CytoSorbents Announces 2020 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Cytosorbents (CTSO) Reports Q4 Revenues Beat
March 9, 2021 4:21 PM ESTCytosorbents (NASDAQ: CTSO) reported Q4 revenue for the quarter came in at $12 million versus the consensus estimate of $10.95 million.
Q4 2020 Results
Q4 2020 total revenue was approximately $12.0 million versus $7.4 million a year agoProduct sales growth accelerated in Q4 2020, with record quarterly product sales of approximately $11.5 million, a 74% increase from $6.6 million in Q4 2019Product gross margins were a record high of 82% in Q4 2020 versus 80% in Q4 2019Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents stated, "In our recent stockholder letter, I discussed how the company successfully navigated a... More
